+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Health and economic benefits of early vaccination and nonpharmaceutical interventions for a human influenza A (H7N9) pandemic: a modeling study



Health and economic benefits of early vaccination and nonpharmaceutical interventions for a human influenza A (H7N9) pandemic: a modeling study



Annals of Internal Medicine 160(10): 684-694



Vaccination for the 2009 pandemic did not occur until late in the outbreak, which limited its benefits. Influenza A (H7N9) is causing increasing morbidity and mortality in China, and researchers have modified the A (H5N1) virus to transmit via aerosol, which again heightens concerns about pandemic influenza preparedness. To determine how quickly vaccination should be completed to reduce infections, deaths, and health care costs in a pandemic with characteristics similar to influenza A (H7N9) and A (H5N1). Dynamic transmission model to estimate health and economic consequences of a severe influenza pandemic in a large metropolitan city. Literature and expert opinion. Residents of a U.S. metropolitan city with characteristics similar to New York City. Lifetime. Societal. Vaccination of 30% of the population at 4 or 6 months. Infections and deaths averted and cost-effectiveness. In 12 months, 48 254 persons would die. Vaccinating at 9 months would avert 2365 of these deaths. Vaccinating at 6 months would save 5775 additional lives and $51 million at a city level. Accelerating delivery to 4 months would save an additional 5633 lives and $50 million. If vaccination were delayed for 9 months, reducing contacts by 8% through nonpharmaceutical interventions would yield a similar reduction in infections and deaths as vaccination at 4 months. The model is not designed to evaluate programs targeting specific populations, such as children or persons with comorbid conditions. Vaccination in an influenza A (H7N9) pandemic would need to be completed much faster than in 2009 to substantially reduce morbidity, mortality, and health care costs. Maximizing non-pharmaceutical interventions can substantially mitigate the pandemic until a matched vaccine becomes available. Agency for Healthcare Research and Quality, National Institutes of Health, and Department of Veterans Affairs.

(PDF emailed within 0-6 h: $19.90)

Accession: 053485464

Download citation: RISBibTeXText

PMID: 24842415

DOI: 10.7326/M13-2071


Related references

Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts. Expert Review of Anti-Infective Therapy 8(12): 1431-1439, 2011

Nonpharmaceutical Interventions for Military Populations During Pandemic Influenza. Turk Silahli Kuvvetleri Koruyucu Hekimlik Bulteni 6(4): 285-290, 2008

Nonpharmaceutical interventions implemented during the 1918-1919 influenza pandemic. JAMA 298(19): 2260; Author Reply 2261-2260; Author Reply 2261, 2007

Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic. JAMA 298(6): 644-654, 2007

Findings, gaps, and future direction for research in nonpharmaceutical interventions for pandemic influenza. Emerging Infectious Diseases 16(4): E2-E2, 2010

Public health emergency preparedness: lessons learned about monitoring of interventions from the National Association of County and City Health Official's survey of nonpharmaceutical interventions for pandemic H1N1. Journal of Public Health Management and Practice 19(1): 70-76, 2013

Use of nonpharmaceutical interventions to reduce transmission of 2009 pandemic influenza A (pH1N1) in Pennsylvania public schools. Journal of School Health 83(4): 281-289, 2013

Household transmission of 2009 pandemic influenza A (H1N1) and nonpharmaceutical interventions among households of high school students in San Antonio, Texas. Clinical Infectious Diseases 52 Suppl 1: S146-S153, 2011

Knowledge, attitudes, and practices of nonpharmaceutical interventions following school dismissals during the 2009 Influenza A H1N1 pandemic in Michigan, United States. Plos One 9(4): E94290-E94290, 2015

The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China. Bmc Infectious Diseases 15(): 284-284, 2016

Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic. Bmc Infectious Diseases 10(): 14-14, 2010

Survey of distribution of seasonal influenza vaccine doses in 201 countries (2004-2015): The 2003 World Health Assembly resolution on seasonal influenza vaccination coverage and the 2009 influenza pandemic have had very little impact on improving influenza control and pandemic preparedness. Vaccine 35(36): 4681-4686, 2017

Using results from infectious disease modeling to improve the response to a potential H7N9 influenza pandemic. Clinical Infectious Diseases 60 Suppl 1: S9-10, 2015

Pandemic vaccination strategies and influenza severe outcomes during the influenza A(H1N1)pdm09 pandemic and the post-pandemic influenza season: the Nordic experience. Euro Surveillance 21(16): -, 2016

The role of nonpharmaceutical interventions during a pandemic. Texas Medicine 103(10): 42-44, 2007